Log in

NASDAQ:GILDGilead Sciences Stock Price, Forecast & News

$78.21
+1.23 (+1.60 %)
(As of 04/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$76.36
Now: $78.21
$79.47
50-Day Range
$66.80
MA: $72.26
$80.23
52-Week Range
$60.89
Now: $78.21
$85.97
Volume19.42 million shs
Average Volume25.64 million shs
Market Capitalization$98.47 billion
P/E Ratio18.58
Dividend Yield3.53%
Beta0.68
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Scholar Rock Holding Corporation; Tango Therapeutics; National Cancer Institute; Pfizer, Inc.; Sangamo Therapeutics, Inc.; Gadeta B.V.; HiFiBiO Therapeutics; Agenus Inc.; HOOKIPA Pharma Inc.; Goldfinch Bio, Inc.; and insitro Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Read More
Gilead Sciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 3.3Dividend Strength: 3.3Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.09 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GILD
CUSIP37555810
Phone650-574-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.45 billion
Cash Flow$7.41 per share
Book Value$17.90 per share

Profitability

Net Income$5.39 billion

Miscellaneous

Employees11,800
Outstanding Shares1,259,020,000
Market Cap$98.47 billion
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive GILD News and Ratings via Email

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.


Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

How has Gilead Sciences' stock been impacted by COVID-19 (Coronavirus)?

Gilead Sciences' stock was trading at $73.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GILD stock has increased by 6.1% and is now trading at $78.21. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Gilead Sciences?

29 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 3 sell ratings, 11 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Gilead Sciences.

When is Gilead Sciences' next earnings date?

Gilead Sciences is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Gilead Sciences.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) announced its quarterly earnings data on Tuesday, February, 4th. The biopharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.67 by $0.37. The biopharmaceutical company earned $5.88 billion during the quarter, compared to the consensus estimate of $5.74 billion. Gilead Sciences had a net margin of 23.99% and a return on equity of 35.49%. The company's revenue was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.44 EPS. View Gilead Sciences' earnings history.

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences declared a quarterly dividend on Tuesday, February 4th. Shareholders of record on Friday, March 13th will be paid a dividend of $0.68 per share on Monday, March 30th. This represents a $2.72 dividend on an annualized basis and a dividend yield of 3.48%. The ex-dividend date is Thursday, March 12th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.63. View Gilead Sciences' dividend history.

What guidance has Gilead Sciences issued on next quarter's earnings?

Gilead Sciences issued an update on its FY20 earnings guidance on Tuesday, February, 4th. The company provided earnings per share guidance of 6.00-6.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.02. The company issued revenue guidance of 21.8-22.2 billion, compared to the consensus revenue estimate of $22.54 billion.

What price target have analysts set for GILD?

29 brokerages have issued 1-year price objectives for Gilead Sciences' shares. Their forecasts range from $60.00 to $95.00. On average, they expect Gilead Sciences' stock price to reach $77.54 in the next twelve months. This suggests that the stock has a possible downside of 0.9%. View analysts' price targets for Gilead Sciences.

What are Wall Street analysts saying about Gilead Sciences stock?

Here are some recent quotes from research analysts about Gilead Sciences stock:
  • 1. Needham & Company LLC analysts commented, "Gilead reported $5.28B in 1Q19 total revenue, in line w/ our $5.27B and consensus $5.3B ests. Product sales were $5.20B (-8% q/q), matching our $5.16B and consensus $5.2B ests. Mgmt had guided for 12-14% sequential decline. All annual guidance unch. Non-GAAP EPS $1.76 was above our $1.64 and consensus $1.61 ests. New CEO O’Day outlined priorities (Strengthen pipeline [internal and external business development]; Ensure optimal commercial delivery; and Reassess organizational structure [‘evolution not revolution’]) and announced that Kite will operate as a separate business unit w/ a new CEO reporting directly to O’Day. Filgotinib MAA to be submitted 3Q19, but no update yet on strategy/ timing for NDA submission. NASH ATLAS drug combination trial results expected 4Q19 (unch). HOLD." (5/6/2019)
  • 2. Cowen Inc analysts commented, "NTLA reported 1Q results of $10.4M in collaboration revenue, $34M in -$0.49 vs consensus EPS of -$0.57. 1Q cash balance was $296.6M, which management estimates will fund operations into 1H 2021. The call included several updates on the pipeline in in-vivo editing and ex-vivo engineered T-Cells: 1) NTLA remains on track for NDA submission of NTLA-2001 for ATTR in 2020 and preparations (manufacturing & toxicology) are ongoing. 2) Data presented at ASGCT was the first demonstration of CRISPR/Cas9-based targeted insertion in the liver of non-human primates. We view this as a validation of NTLA’s modular LNP+AAV approach to in-vivo editing. 3) ASGCT presentation on engineered cell therapy (WT1 insertion into >95% of isolated T-cells) shows progress in cell therapy." (5/3/2019)
  • 3. According to Zacks Investment Research, "Gilead’s HIV franchise maintains momentum, driven by continued uptake of Genvoya and Odefsey, and the rapid adoption of Biktarvy. However, the company’s HCV franchise continues to witness a slowdown across key markets, including the United States and Europe, as a result of competition and pricing pressure. Consequently, Gilead shifted focus to its HIV franchise, and newer avenues like CAR-T therapy and NASH. However, the company suffered a setback with the failure of a late-stage study on selonsertib in patients with compensated cirrhosis (F4) due to NASH. Shares have underperformed the industry in the past three months." (5/2/2019)
  • 4. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $87 Price Target. We do not think today’s announcement that GILD’s STELLAR3 study was unsuccessful will be met with much surprise after the previous STELLAR4 failure: no changes to our estimates. The fibrosis improvement was least for the high dose and greatest for the placebo with a p-value at the higher dose of 0.42 and at lower dose it was 0.93. After both STELLAR Ph3 readouts we are focused on how Gilead will advance its strategy in NASH; we think M&A could be a strategy." (4/25/2019)
  • 5. Mizuho analysts commented, "DERM is a leading dermatology company with commercial and pipeline advancements that could drive upwards earnings revisions and the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $25." (4/22/2019)

Has Gilead Sciences been receiving favorable news coverage?

News headlines about GILD stock have trended very negative on Sunday, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Gilead Sciences earned a news impact score of -3.3 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutGilead Sciences.

Are investors shorting Gilead Sciences?

Gilead Sciences saw a increase in short interest in March. As of March 13th, there was short interest totaling 26,584,200 shares, an increase of 11.9% from the February 27th total of 23,760,000 shares. Based on an average daily trading volume, of 25,235,700 shares, the short-interest ratio is currently 1.1 days. Currently, 2.1% of the shares of the stock are sold short. View Gilead Sciences' Current Options Chain.

Who are some of Gilead Sciences' key competitors?

What other stocks do shareholders of Gilead Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include Alibaba Group (BABA), Walt Disney (DIS), Intel (INTC), Micron Technology (MU), Celgene (CELG), NVIDIA (NVDA), Netflix (NFLX), AbbVie (ABBV), AT&T (T) and Bank of America (BAC).

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the following people:
  • Ms. Robin L. Washington, CFO & Exec. VP (Age 56)
  • Dr. John G. McHutchison M.D., FRACP, Chief Scientific Officer and Head of R&D (Age 61)
  • Mr. Gregg H. Alton, Chief Patient Officer (Age 53)
  • Ms. Laura Hamill, Exec. VP of Worldwide Commercial Operations (Age 54)
  • Mr. Daniel O'Day, Chairman & CEO (Age 55)

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Nexus Investment Management Inc. (0.02%), Private Asset Management Inc. (0.01%), Cullinan Associates Inc. (0.01%), First Financial Bank Trust Division (0.01%), Fulton Bank N.A. (0.01%) and Stillwater Investment Management LLC (0.00%). Company insiders that own Gilead Sciences stock include Brett A Pletcher, Gayle E Wilson, John C Martin, John Francis Cogan, Olsen Per Wold and Richard James Whitley. View institutional ownership trends for Gilead Sciences.

Which institutional investors are selling Gilead Sciences stock?

GILD stock was sold by a variety of institutional investors in the last quarter, including Private Asset Management Inc., and Neville Rodie & Shaw Inc.. Company insiders that have sold Gilead Sciences company stock in the last year include Brett A Pletcher, Gayle E Wilson, John Francis Cogan, and Olsen Per Wold. View insider buying and selling activity for Gilead Sciences.

Which institutional investors are buying Gilead Sciences stock?

GILD stock was purchased by a variety of institutional investors in the last quarter, including Cullinan Associates Inc., First Financial Bank Trust Division, Nexus Investment Management Inc., IMS Capital Management, Wiley BROS. Aintree Capital LLC, Fulton Bank N.A., and Stillwater Investment Management LLC. View insider buying and selling activity for Gilead Sciences.

How do I buy shares of Gilead Sciences?

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $78.21.

How big of a company is Gilead Sciences?

Gilead Sciences has a market capitalization of $98.47 billion and generates $22.45 billion in revenue each year. The biopharmaceutical company earns $5.39 billion in net income (profit) each year or $6.14 on an earnings per share basis. Gilead Sciences employs 11,800 workers across the globe. View additional information about Gilead Sciences.

What is Gilead Sciences' official website?

The official website for Gilead Sciences is http://www.gilead.com/.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]

This page was last updated on 4/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel